Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals Drug

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development

Fineline Cube Jun 26, 2025

US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....

Company Drug

LG Chem’s Cross-Linked Sodium Hyaluronate Gel Gains NMPA Approval for Midface Use

Fineline Cube Jun 26, 2025

South Korea’s LG Chem announced that its cross-linked sodium hyaluronate gel with lidocaine has received...

Company Deals

Porton Advanced Partners With EVA Pharma to Boost CAR-T Cell Therapy in MENA

Fineline Cube Jun 26, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a...

Company Drug

Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis

Fineline Cube Jun 26, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA)...

Company Deals

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD

Fineline Cube Jun 26, 2025

US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...

Company Drug

SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation

Fineline Cube Jun 26, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced this week that...

Company Drug

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter

Fineline Cube Jun 26, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Oncolytic Immunotherapy Pipeline

Fineline Cube Jun 26, 2025

Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong...

Company Drug

Genevector’s JWK002 Gains NMPA IND Approval for XLRS Gene Therapy

Fineline Cube Jun 26, 2025

China-based Chengdu Geneector Biotechnology Co., Ltd. (Genevector), a developer of AAV gene therapy drugs, announced...

Company Deals

CMS Plans Secondary Listing on Singapore Exchange to Enhance Shareholder Base and Liquidity

Fineline Cube Jun 25, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867) announced its proposal for a secondary listing...

Company Drug

Livzon’s YJH-012 siRNA Drug Gets NMPA Green Light for Gout Trials

Fineline Cube Jun 25, 2025

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513) announced that its Category 1 chemical drug YJH-012...

Company Medical Device

GE Healthcare Wins FDA Approval for Vizamyl Label Update in Alzheimer’s Detection

Fineline Cube Jun 25, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Policy / Regulatory

NHSA Emphasizes Management of Designated Medical Institutions for Healthcare Quality

Fineline Cube Jun 25, 2025

The National Healthcare Security Administration (NHSA) this week released a notification emphasizing the importance of...

Company Deals

Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services

Fineline Cube Jun 25, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...

Company Drug

Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia

Fineline Cube Jun 25, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations...

Company Drug

Henlius Biotech Doses First Patient in Japanese Bridging Trial of Serplulimab for ES-SCLC

Fineline Cube Jun 25, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced the successful completion of first patient dosing...

Company Drug

C.Q. Pharma’s Prasugrel Clinical Filing Accepted by China’s NMPA

Fineline Cube Jun 25, 2025

China-based C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950) announced that its clinical application for prasugrel...

Company Drug

BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China

Fineline Cube Jun 25, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...

Company Deals

TINGSN Technology Secures RMB 100M in Series B+ Round for 4D Intracardiac Ultrasound R&D

Fineline Cube Jun 25, 2025

China-based TINGSN Technology has reportedly secured RMB 100 million (USD 14 million) in a Series...

Company Deals

Bayer and Tsinghua University Renew Strategic Research Pact for Drug Innovation

Fineline Cube Jun 25, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their...

Posts pagination

1 … 138 139 140 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.